Search | Clinical Trials Finder

Conditions: Macular Degeneration
Interventions: Anecortave Acetate 15 mg sterile suspension, Photodynamic Therapy (PDT); Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 50 Years and older
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Chronic Graft vs. Host Disease, Graft vs Host Disease, Graft-Versus-Host Disease
Interventions: Extracorporeal Photopheresis (ECP), Methoxsalen; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lung Non-Small Cell Carcinoma, Pleural Disorder
Interventions: Porfimer Sodium, Video-Assisted Thoracic Surgery, Photodynamic Therapy, Intraoperative PDT; Drug · Procedure · Device
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Dermatitis, Psoriasis
Interventions: Narrowband Ultraviolet B (TL-01UVB) Therapy, Topical Psoralen plus ultraviolet A (PUVA); Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Non Small Cell Lung Cancer
Interventions: Photodynamic Therapy, Argon Plasma Coagulation; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Down Syndrome (DS), Keratoconus, Pellucid Marginal Degeneration, Forme Fruste Keratoconus (FFK)
Interventions: Epi-ON corneal cross-linking (CXL); Combination Product
Lead sponsor: Woolfson Eye Institute; Other
Eligibility: 8 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 12
States / cities: Atlanta, Georgia • Canton, Georgia • Cumming, Georgia + 8 more

Conditions: Cutaneous Squamous Cell Carcinoma
Interventions: Aminolevulinic acid hydrochloride 10% topical gel with Red Light; Combination Product
Lead sponsor: The Center for Clinical and Cosmetic Research; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Aventura, Florida

Conditions: Basal Cell Carcinoma, Basal Cell Nevus Syndrome
Interventions: Dietary Vitamin D3 pre-treatment, Photodynamic therapy, Serum Maintenance Vitamin D3; Drug · Radiation
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Not listed
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Phoenix, Arizona • Cleveland, Ohio

Conditions: Actinic Keratoses, Skin Neoplasms
Interventions: Aminolevulinic Acid, Vehicle; Drug · Other
Lead sponsor: DUSA Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 7
States / cities: Irvine, California • San Francisco, California • Miami, Florida + 4 more

Conditions: Psoriasis
Interventions: Topical Therapy, Phototherapy and Systemic Therapy, Biologic Therapy; Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Irvine, California

Conditions: Actinic Keratoses
Interventions: BF-200 ALA and red light LED lamp; Combination Product
Lead sponsor: Biofrontera Bioscience GmbH; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cholangiocarcinoma, Biliary Stricture, Biliary Obstruction, Bile Duct Cancer
Interventions: Photodynamic Therapy; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Graft Versus Host Disease
Interventions: Aldesleukin, Extracorporeal Photopheresis, Laboratory Biomarker Analysis, Quality-of-Life Assessment; Biological · Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Duarte, California

Conditions: Neurofibroma
Interventions: LS11; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 3 Years to 21 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: NEUROFIBROMATOSIS 1
Interventions: aminolevulinic acid; Drug
Lead sponsor: Donald Basel; Other
Eligibility: 14 Years to 30 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Actinic Keratosis, Keratosis, Actinic, Keratosis
Interventions: BF-200 ALA and red light LED lamp; Combination Product
Lead sponsor: Biofrontera Bioscience GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 9
States / cities: Phoenix, Arizona • Greenwood Village, Colorado • Indianapolis, Indiana + 5 more

Conditions: Transitional Cell Cancer of Renal Pelvis and Ureter
Interventions: padeliporfin VTP; Drug
Lead sponsor: Steba Biotech S.A.; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 12
States / cities: Irvine, California • Los Angeles, California • Atlanta, Georgia + 9 more

Conditions: Acne Vulgaris
Interventions: Methyl aminolevulinate (MAL) PDT; Drug
Lead sponsor: Photocure; Industry
Eligibility: 15 Years to 40 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 2
States / cities: Naperville, Illinois • Albuquerque, New Mexico

Conditions: Amputation, Osseointegration
Interventions: 5-aminolevulinic acid (5-ALA), Photodynamic therapy (PDT); Drug · Device
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Fruste Keratoconus, Risk of Ectasia
Interventions: Corneal Cross-Linking, Riboflavin; Device · Drug
Lead sponsor: Cxlusa; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 8
States / cities: Scottsdale, Arizona • San Diego, California • Miami, Florida + 5 more

Conditions: Actinic Keratosis
Interventions: Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%, Vehicle, Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E.; Drug · Other · Device
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 20
States / cities: Phoenix, Arizona • Fremont, California • Castle Rock, Colorado + 17 more

Conditions: Chronic Graft Versus Host Disease
Interventions: ECP Methoxsalen, Standard of Care; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 11
States / cities: Miami, Florida • Indianapolis, Indiana • New Orleans, Louisiana + 7 more

Conditions: Skin Cancer, Signs and Symptoms
Interventions: Modulated Imaging (MI), Photodynamic therapy; Device · Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Irvine, California

Conditions: Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Interventions: Ruvidar® (TLD-1433) bladder infusion and PDT; Combination Product
Lead sponsor: Theralase® Technologies Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 10
States / cities: Chicago, Illinois • Greenwood, Indiana • Syracuse, New York + 7 more

Search by objective public record fields.

Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD

Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD

Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease

Study to Compare Different Light Therapies (Narrowband Ultraviolet B vs PUVA) for Hand and Foot Skin Diseases.

Trial of Photodynamic Therapy Versus Argon Plasma Coagulation for Lung Cancer With Endobronchial Obstruction

Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome

Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma

ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients

Evaluation of Vitamin D Levels in Psoriasis Patients

Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK)

Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma

Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Graft-Versus-Host Disease

Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas

Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II

Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study

Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris

Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients

Combined CXL//UV and PRK or LASIK in Forme Fruste Keratoconus or Eyes With Potential Risk of Ectasia

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities

Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)

Optimizing Photodynamic Therapy of Cutaneous Neoplastic Diseases Via Structured Illumination and Real-time Dosimetry.

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients